SAN FRANCISCO, March 08, 2016 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report that reveals a largely untapped opportunity for sales teams in Life Sciences companies; integrating global health data and predictive insights into their commercial efforts. This latest report, “Navigating your way to insights-driven customer relationships,” published in conjunction with pharmaphorum, found that the majority of both management and frontline staff see current Customer Relationship Management (CRM) systems as a valuable tool for managing activities and customers, yet to date has not helped field teams find actions for sales strategy and planning.
"Bringing predictive capabilities and insights into customer engagement strategies and solutions is a nascent but growing opportunity for Life Sciences companies to improve sales effectiveness,” said Lance Scott, chief executive officer, Zephyr Health. “We consistently hear from our customers that they want more from their existing systems, and they recognize the immense value in having market and customer intelligence integrated into their CRM for competitive advantage.”
The “Navigating Your Way to Insights-Driven Customer Relationships” survey assessed 107 frontline sales and management staff to determine where the Life Sciences industry is in its own journey of improving customer engagement. The final report provides insights and recommendations to transform customer engagement and put forward a more proactive and predictive sales strategy. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health is the leading insights-as-a-service company harnessing the power of the global health data to address critical business and patient needs. Zephyr Illuminate™ helps Life Sciences companies - pharmaceutical, biotech and medical device –make confident decisions faster across the entire product lifecycle with precise and predictive insights. From pre-launch to product maturity, our solutions connect data from thousands of sources across the global healthcare ecosystem to produce deep, predictive insights that our customers use to instrument their business and dramatically improve product lifecycle performance. Zephyr Health's customers include 4 of the Top 10 Pharmaceutical companies, 2 of the Top 10 Biotech Companies and 2 of the Top 10 Medical Device companies.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media Contact: Zephyr Health Global Communications [email protected]


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



